The Abigail Alliance for Better Access to Developmental Drugs
seeks broader availability of investigational drugs on behalf of
terminally ill patients. It believes that patients have a right to
decide, for themselves, whether to take an investigational drug that the
FDA has approved for clinical trials. The FDA currently restricts
access to those drugs to patients in clinical trials and patients who
get a compassionate use exemption, which the Abigail Alliance believes
is unduely burdensome.[1]
The Abigail Alliance is best known for a legal case, which it lost, Abigail Alliance v. von Eschenbach, in which it was represented by the Washington Legal Foundation. On August 7, 2007, in an 8-2 ruling, the U.S. Court of Appeals for the District of Columbia Circuit reversed an earlier ruling in favor of the Alliance.[citation needed]
In 2008, the Supreme Court of the United States declined to hear their appeal[2] This decision left standing the appellate court decision that terminally ill patients have no legal right to demand "a potentially toxic drug with no proven therapeutic benefit."
The Abigail Alliance is a 501(c)(3) non-profit organization, incorporated in Virginia in 2001.
The Abigail Alliance is best known for a legal case, which it lost, Abigail Alliance v. von Eschenbach, in which it was represented by the Washington Legal Foundation. On August 7, 2007, in an 8-2 ruling, the U.S. Court of Appeals for the District of Columbia Circuit reversed an earlier ruling in favor of the Alliance.[citation needed]
In 2008, the Supreme Court of the United States declined to hear their appeal[2] This decision left standing the appellate court decision that terminally ill patients have no legal right to demand "a potentially toxic drug with no proven therapeutic benefit."
The Abigail Alliance is a 501(c)(3) non-profit organization, incorporated in Virginia in 2001.
